Search the web
Sign In
New User? Sign Up
FA_babelFAmily · FA_babelFAmily
? Already a member? Sign in to Yahoo!

Yahoo! Groups Tips

Did you know...
Real people. Real stories. See how Yahoo! Groups impacts members worldwide.

Best of Y! Groups

   Check them out and nominate your group.
Having problems with message search? Fill out this form to ensure your group is one of the first to be migrated to the new message search system.

Messages

  Messages Help
Advanced
Messages 2044 - 2074 of 3331   Newest  |  < Newer  |  Older >  |  Oldest
Messages: Show Message Summaries   (Group by Topic) Sort by Date v  
#2074 From: "FEDAES" <acampo4@...>
Date: Fri Aug 1, 2008 10:44 pm
Subject: Re: Isabelle
acampo4@...
Send Email Send Email
 
Mis condolencias para la familia de Isabelle por su pérdida, y también pos
lo que supone que uno de nosotros haya fallecido.
Isabel
----- Original Message -----
From: "Miguel" <mcibrianarrakis@...>
To: "Mary Kearney" <drkearney@...>
Cc: "HispAtaxia" <HispAtaxia@yahoogroups.com>; "FA Babel-FAmily"
<FA_BabelFAmily@yahoogroups.com>
Sent: Monday, July 28, 2008 9:47 PM
Subject: RE: [FA_babelFAmily] Isabelle


> Lamento la muerte de Isabelle. Con mis abrazos a su familia, quiero
> trasmitirles mi mensaje  de condolencia.
>
> Miguel-A. (paciente de ataxia de Friedreich).
> --------------------
>
> -----Mensaje original-----
> De: FA_babelFAmily@yahoogroups.com
> [mailto:FA_babelFAmily@yahoogroups.com]En nombre de Mary Kearney
> Enviado el: domingo, 27 de julio de 2008 23:07
> Para: FA_babelFAmily@yahoogroups.com
> Asunto: [FA_babelFAmily] Isabelle
>
>
> Hi
>
> I am sorry to hear of Isabelles death, Please convey my sympathy to
> Phillippe
>
>
> Mary Kearney Ireland
>
> ------------------------------------
>
> Yahoo! Groups Links
>
>
>
>
>
>
>
> ------------------------------------
>
> Yahoo! Groups Links
>
>
>
>

#2073 From: "Gian Piero Sommaruga" <gsommaruga@...>
Date: Thu Jul 31, 2008 3:23 pm
Subject: ENG: Rare Sleep-Activated Neurons Identified in the Cerebral Cortex
gsommaruga@...
Send Email Send Email
 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2036 (ITA)

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2057 (ESP)

 

 

 

 

http://finance.boston.com/boston?GUID=6067499&Page=MediaViewer&ChannelID=3198

 

 

SRI International Research Team Identifies Rare Sleep-Activated Neurons in the Cerebral Cortex

 

Findings May Have Important Implications for Treatment of Sleep Disorders and for Understanding Mood and Memory

MENLO PARK, CA -- (MARKET WIRE) -- 07/21/08 -- SRI International announced today that a research team has identified the first example of neurons that are activated in the cerebral cortex during slow wave sleep (SWS). The research, led by Dmitry Gerashchenko and Thomas Kilduff, will be published in the Proceedings of the National Academy of Sciences (PNAS) in a paper titled "Identification of a Population of Sleep-Active Cerebral Cortex Neurons." The paper is available via the PNAS Web site starting July 21.

The presence of slow waves in the electroencephalogram (EEG) is the distinctive "signature" of SWS and a type of activity that does not normally occur during wakefulness. For years, researchers have hypothesized that 'slow-wave activity' (SWA) is correlated with the recuperative properties of sleep and the brain's ability to learn, in part, because brain cells are relatively quiet during this time. While populations of neurons activated during sleep have been identified in the forebrain and the hypothalamus, up until this point, neurons in the cortex have been seen as dormant. These new results show that a group of rare neurons are active, rather than at rest, during SWS.

"To date, the role of the cortex in SWA has been a mystery since all cortical cells were thought to be quiescent during SWS," said SRI's Dmitry Gerashchenko. "We have discovered that the cortex not only plays a role, but harbors a small population of neurons that is activated during spontaneous and catch-up sleep, which occurs after sleep deprivation."

The authors found that these neurons are active in the cortex of three species (mice, rats and hamsters) during SWS. "Since these neurons also exist in the human brain, they likely 'turn on' while we sleep as well," said SRI's Thomas Kilduff, senior director of Neurobiology at SRI in whose laboratory at SRI the work was conducted. Kilduff is also a consulting professor at Stanford University School of Medicine. "As such, these neurons will be important to study in sleep disorders such as insomnia. Activation of these cells during sleep may have important implications for aspects of our behavior and cognitive activities that depend heavily on sleep, such as our daytime performance, memory and mood."

The research also found that the type of neurons that are "turned on" during sleep are the rarest of all currently known cortical neurons. These cells express the enzyme neuronal nitric oxide synthase (nNOS) and thus make nitric oxide (NO), which regulates blood flow in the brain and periphery.

A notable feature of these results is that the proportion of nNOS neurons that are activated seems to be related to the magnitude of homeostatic sleep drive; that is, the longer animals are kept awake, the more nNOS neurons are activated when the animals finally go to sleep. Additionally, nNOS neurons are the only inhibitory cell type known to have long projections both within and between the two hemispheres of the brain.

"The next step will be to determine whether these neurons are the 'superhighway' that conducts slow waves across the cortex during sleep," Kilduff continued.

The research was conducted by Dmitry Gerashchenko (SRI International), Jonathan P. Wisor (SRI International), Deirdre Burns (SRI International), Rebecca K. Reh (University of Washington), Priyattam J. Shiromani (West Roxbury VA Medical Center and Harvard Medical School), Takeshi Sakurai (Kanazawa University), Horacio O. de la Iglesia (University of Washington), and Thomas S. Kilduff (SRI International and Stanford University School of Medicine).

The research was supported by the National Heart, Lung and Blood Institute, National Institute of Aging, National Institute of Mental Health, and the Sleep Research Society Foundation.

Gerashchenko presented the team's findings at the SLEEP 2008 symposium, "New Developments in Sleep Research: Molecular Genetics, Gene Expression and Systems Neurobiology" on Monday, June 9. For details on the symposium, visit: http://www.sleepmeeting.org/.

About SRI International

Silicon Valley-based SRI International (www.sri.com) is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients and partners for more than 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, businesses, and foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.

Media Contact:
Lindsay Sheppard
SRI International
(650) 859-2491

 

 

 

 


#2072 From: "Gian Piero Sommaruga" <gsommaruga@...>
Date: Thu Jul 31, 2008 9:07 am
Subject: ENG: Alzheimer's Curbed By Promising New Drug
gsommaruga@...
Send Email Send Email
 
#2071 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Wed Jul 30, 2008 8:32 pm
Subject: ENG: US Genetic Info Non-descrimination Act
gippirintronet
Offline Offline
Send Email Send Email
 
 
----- Original Message -----
From: "Tom Sathre" <tsathre@...>
To: "Gian Piero Sommaruga (casa)" <gippi@...>
Sent: Wednesday, July 30, 2008 10:08 PM
Subject: US Genetic Info Non-descrimination Act

Gian,
 
Here is an article about discrimination that we ataxians find relevant. I recomend posting this article for FABabelFamily. This article is from NIH.
 
Tom.
 

 

 

URL of this page: http://www.genome.gov/24519851

 

Genetic Information Nondiscrimination Act: 2007-2008

President Bush Signs Genetic Information Nondiscrimination Act of 2008 New

President George W. Bush signs H.R. 493, the Genetic Information Nondiscrimination Act of 2008, Wednesday, May 21, 2008, in the Oval Office. White House photo by Eric Draper.Washington, Wed., May 21 2008 — The President has signed into law the Genetic Information Nondiscrimination Act (GINA) that will protect Americans against discrimination based on their genetic information when it comes to health insurance and employment. The bill had passed the Senate unanimously and the House by a vote of 414 to 1. The long-awaited measure, which has been debated in Congress for 13 years, will pave the way for people to take full advantage of the promise of personalized medicine without fear of discrimination.

Read more: President Bush Signs H.R. 493, the Genetic Information Nondiscrimination Act of 2008 [whitehouse.gov]

The history of GINA's passage through the legislative process, 2007-2008, can be tracked on this page.



2007

Legislative Chronology

House Resolution (H.R.) 493: The Genetic Information Nondiscrimination Act of 2007 [thomas.loc.gov]

All Actions (All links are on Thomas.loc.gov, the legislative information resource from the Library of Congress):

    • January 16, 2007: Introductory remarks on measure: Hon. Louise M. Slaughter
    • January 16, 2007: Referred to the Committee on Education and Labor, and in addition to the Committees on Energy and Commerce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
    • January 16, 2007: Referred to House Education and Labor
      • February 14, 2007: Committee Consideration and Mark-up Session Held
      • February 14, 2007: Ordered to be Reported (Amended) by Voice Vote
    • January 16, 2007: Referred to House Energy and Commerce
    • January 16, 2007: Referred to House Ways and Means
    • January 18, 2007: Referred to the Subcommittee on Health
    • March 5, 2007 at 3:47p.m.: Reported (Amended) by the Committee on Education and Labor. H. Rept. 110-28, Part I
    • March 5, 2007 at 3:48 p.m.: House Committee on Energy and Commerce Granted an extension for further consideration ending not later than March 23, 2007
    • March 5, 2007 at 3:49 p.m.: House Committee on Ways and Means Granted an extension for further consideration ending not later than March 23, 2007.
    • March 21, 2007: House committee/subcommittee actions: Ordered to be Reported (Amended) by Voice Vote
    • March 26, 2007: Reported (Amended) by the Committee on Ways and Means. H. Rept. 110-28, Part II.
    • March 29, 2007: Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 110-28, Part III.
    • March 29, 2007: Placed on the Union Calendar, Calendar No. 46.
      The Union Calendar is the list of bills available for consideration to the Committee of the Whole. Bills are referred to the Union Calendar if they directly or indirectly deal with money.
    • April 25, 2007: House passes act.
2008
    • May 1, 2008:Introduced in House
    • May 1, 2008:Passed/agreed to in House: On motion to suspend the rules and agree to the resolution Agreed to by voice vote.
    • May 1, 2008:Passed/agreed to in Senate: Received in the Senate, considered, and agreed to without amendment by Unanimous Consent.
    • May 21, 2008: President Bush Signs H.R. 493, the Genetic Information Nondiscrimination Act of 2008

Senate Bill (S.) 358: The Genetic Information Nondiscrimination Act of 2007 [thomas.loc.gov]

All Actions (All links are on Thomas.loc.gov, the legislative information resource from the Library of Congress):

    • January 22, 2007: Introductory remarks on measure : Sen. Olympia J. Snowe
    • January 22, 2007: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
    • January 31, 2007: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
    • March 29, 2007: Committee on Health, Education, Labor, and Pensions. Reported by Senator Kennedy with an amendment in the nature of a substitute. Without written report.
    • March 29, 2007: Placed on Senate Legislative Calendar under General Orders. Calendar No. 97.
    • April 10, 2007: By Senator Kennedy from Committee on Health, Education, Labor, and Pensions filed written report. Report No. 110-48
2008
    • April 24, 2008: Passed/agreed to in Senate: Passed Senate with an amendment by Yea-Nay Vote. 95 - 0. Record Vote Number: 113.
    • May 5, 2008: Resolving differences — House actions: On motion that the House agree to the Senate amendment Agreed to by the Yeas and Nays: 414 - 1 (Roll no. 234).
    • May 5, 2008: Cleared for White House.
    • May 21, 2008: President Bush Signs H.R. 493, the Genetic Information Nondiscrimination Act of 2008

Top of page


Last Updated: May 21, 2008

 

 


#2070 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Sun Jul 27, 2008 6:30 pm
Subject: ITA: Un trial clinico cercherà di dimostrare l'efficacia di Algatrium Plus nei soggetti affetti da Atassia
gippirintronet
Offline Offline
Send Email Send Email
 

 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2030 (ESP)

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2033 (ENG)

 

Traduzione: Dott.ssa Stefania Grasso

  

 

http://www.bureaudeprensa.com/es/view.php?bn=bureaudeprensa_salu&key=1215676991

 

 

Spagna – Brudy Technology

 

10 luglio 2008

 

 

Un trial clinico cercherà di dimostrare l’efficacia di Algatrium Plus nei soggetti affetti da Atassia.

 

L’Associazione spagnola Ataxias en Movimiento (Atassie in Movimento) sta collaborando ad un trial clinico atto a ridurre lo stress ossidativo nei pazienti con atassia grazie all’apporto di Algatrium Plus, un’unica molecola specifica di DHA che si è  dimostrata efficace nell’attivazione del sistema cellulare antiossidante.

 

Questo studio, iniziato la settimana scorsa, è mirato a dimostrare una riduzione del danno ossidativo in soggetti affetti da Atassia in modo che essi possano ottenere un trattamento con Algatrium Plus. Ventidue soggetti, principalmente con Atassia di Friedreich (18) e proporzionalmente altri quattro con altre forme di atassia  stanno prendendo parte a questo trial. L’età dei partecipanti varia dai 20 ai 40 anni, ad ecccezione di una ragazza di 17 anni e due pazienti di 62 anni.  Questo studio proseguirà per tre mesi; i partecipanti verranno sottoposti mediamente a tre analisi per valutare la diminuzione dello stress ossidativo. Algatrium Plus consiste in una sostanza sicura in quanto ha superato con successo le prime due fasi fondamentali, inclusa quella della mancanza di tossicità. Se al termine di questo periodo i risultati saranno quelli attesi, il trattamento continuerà in modo indefinito  e sarà disponibile per tutti i pazienti affetti da atassia. Secondo Isabel González dell’Associazione Ataxias en Movimiento: “Il punto principale è che una volta rivelati i risultati, una volta dimostrati i risultati positivi, le conclusioni verranno inoltrate alle autorità sanitarie e alle istituzioni in modo tale che Algatrium Plus possa essere fornito gratuitamente alle persone affette da questa patologia”. Joan Carles Domingo,  chimico dell’Università di Barcellona e coordinatore di questo trial in qualità di ricercatore presso il dipartimento di ricerca di Brudy Technology, ha affermato: ”Entro tre mesi attendiamo una conferma della riduzione del danno ossidativo e a lungo andare un crollo in tutte le patologie correlate che possono colpire le persone affette da atassia, come il diabete o la perdita della visione periferica. Speriamo anche di osservare una riduzione nella gravità delle depressioni, spesso causate da malattie di questo genere”. Le atassie rappresentano una condizione caratterizzata da una perdita progressiva della coordinazione del movimento del corpo. Si tratta di un processo degenerativo altamente debilitante per il quale non esiste ancora un trattamento efficace. L’Associazione Ataxias en Movimiento sostiene una battaglia incessante per eradicare questa malattia e migliorare la qualità di vita delle persone colpite da questa patologia. Per Isabel González: ”Le atassie non hanno mai suscitato l’interesse dell’industria farmaceutica ma dopo aver ricevuto petizioni dai pazienti che stavano già assumendo Algatrium Plus per conto proprio abbiamo contattato i ricercatori della Brudy Technology  che ci hanno dimostrato il loro interesse per le malattie genetiche e, soprattutto, per portare avanti questo progetto”.  

 

°°°°°°°°

 

 

Nota di FA_babelFAmily:

 

sul DHA e Brudy Technology vedi anche

http://health.groups.yahoo.com/group/FA_babelFAmily/message/1803 (ITA)

 


#2069 From: "Gian Piero Sommaruga" <gsommaruga@...>
Date: Wed Jul 30, 2008 3:57 pm
Subject: ENG: message from Daniela
gsommaruga@...
Send Email Send Email
 

 

 

 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2044 (ITA)

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2058 (ESP)

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2063 (FRA)

 

Translated by Tom Sathre

 

Note from babelFAmily:  Daniela is an Italian patient with Friedreich’s ataxia, undergoing treatment with Deferiprone (an iron chelator) and Lokomat (specialized physical therapy).  For more information, go to the following link:

http://health.groups.yahoo.com/group/FA_babelFAmily/message/1508 (ENG)

 

Message from Daniela to Gian Piero Sommaruga, distributed with Daniela’s approval

 

From: Daniela

For: “gippi”

Sent on: Wednesday July 23, 2008 9:44 PM

Topic: Greetings

 

Hi Giampi,

 

First of all I would like to say hello, because vacation time is approaching, and before long, I’ll be going off;  besides, I wanted to keep you informed about how it’s going for me.

Up to now I have been able to maintain the improvements I made in the hospital, and I also have better truncal and neck posture, together with better movements and coordination.

In some manual movements and some exercises, such as putting pegs in holes and handling the Rubik’s cube, I have been able to do it faster and more correctly.

My muscle mass has increased a little all over my body.

I have improved my standing posture when I am upright with my weight on both legs, and also my voice is clearer.

See you soon and happy vacation!

 

Dany

 

 

 


#2068 From: "Tom Sathre" <tsathre@...>
Date: Tue Jul 29, 2008 10:25 pm
Subject: RE: ENG: Putting Drug Development in Patients' Hands
tsathre@...
Send Email Send Email
 
Gian,
 
This approach was used on my wife last May when she was in hospital. She reported a good experience.
 
Tom.
 
------------------------------------
Tom Sathre
(801)640-8602 (F - be careful about the area code!)
(303)794-6351 (H)
----- Original Message -----
Sent: 7/29/2008 3:15:06 PM
Subject: [FA_babelFAmily] ENG: Putting Drug Development in Patients' Hands
 
Hello,
I found this interesting article, though not talking about the FA,  ¡¡¡¡  we have too little presence in the media  !!!!!!, I think that explains very well the importance of associations concerned and individual efforts to push forward in search of a cure.

Putting Drug Development in Patients' Hands
 
 
Greetings
 
Juan Carlos


#2067 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Tue Jul 29, 2008 9:15 pm
Subject: ENG: Putting Drug Development in Patients' Hands
gippirintronet
Offline Offline
Send Email Send Email
 
 
 
Hello,
I found this interesting article, though not talking about the FA,  ¡¡¡¡  we have too little presence in the media  !!!!!!, I think that explains very well the importance of associations concerned and individual efforts to push forward in search of a cure.

Putting Drug Development in Patients' Hands
 
 
Greetings
 
Juan Carlos


#2066 From: "Maria Litani" <marialita@...>
Date: Tue Jul 29, 2008 4:27 pm
Subject: Re: FRA: adieu à Isabelle
marialita@...
Send Email Send Email
 
La morte di Isabelle è una grande perdita per tutti quelli che l'hanno conosciuta, le hanno voluto bene ed hanno condiviso con lei la lotta contro l'atassia.
Ammirevole esempio di forza.
Invio le mie personali condoglianze alla famiglia ed unisco la partecipazione dell'AISA (Associazione Italiana per la lotta alle Sindromi Atassiche).
Maria Litani
(mamma di Stefano FA 30 e Lucia FA 25)
Segretaria Generale AISA Onlus
 
----- Original Message -----
Sent: Saturday, July 26, 2008 11:48 PM
Subject: [FA_babelFAmily] FRA: adieu à Isabelle

 
 
Emis par Sylvie le: Sam 26 Juil 2008 à 20:13     Sujet du message: adieu à isabelle
        
bonjour tous

je reviens auprès de vous avec une bien triste nouvelle qui me bouleverse énormément... philippe hennebert vient de m'appeler pour m'annoncer qu'isabelle sa jeune épouse AF est décédée jeudi soir...

malgré la maladie isabelle rayonnait de joie de vivre... et elle avait trouvé l'amour de sa vie auprès de philippe pour qui elle était tout... ils étaient si beaux tous les deux...

isabelle de là où tu es j'espere que tu vois tous ceux qui t'aiment et que tu es en paix...
philippe je fais l'impossible pour venir auprès de toi lundi dire adieu à isabelle, tu peux compter sur moi et sur mon amitié... tient bon mon ami... je suis déjà avec toi...

philippe et isabelle en avril dernier :


#2065 From: "Miguel" <mcibrianarrakis@...>
Date: Mon Jul 28, 2008 8:59 pm
Subject: RV: Isabelle
mcibrianarrakis
Offline Offline
Send Email Send Email
 
Lamento la muerte de Isabelle. Con mis abrazos a su familia, quiero
trasmitirles mi mensaje  de condolencia.

Miguel-A. (paciente de ataxia de Friedreich).
--------------------

-----Mensaje original-----
De: FA_babelFAmily@yahoogroups.com
[mailto:FA_babelFAmily@yahoogroups.com]En nombre de Mary Kearney
Enviado el: domingo, 27 de julio de 2008 23:07
Para: FA_babelFAmily@yahoogroups.com
Asunto: [FA_babelFAmily] Isabelle


Hi

I am sorry to hear of Isabelles death, Please convey my sympathy to
Phillippe


Mary Kearney Ireland

------------------------------------

Yahoo! Groups Links

#2064 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Mon Jul 28, 2008 8:41 pm
Subject: ITA: Un trial clinico cercherà di dimostrare l'efficacia di Algatrium Plus nei soggetti affetti da Atassia
gippirintronet
Offline Offline
Send Email Send Email
 
 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2033 (ENG)

 

Traduzione: Dott.ssa Stefania Grasso

  

 

http://www.bureaudeprensa.com/es/view.php?bn=bureaudeprensa_salu&key=1215676991

 

 

Spagna – Brudy Technology

 

10 luglio 2008

 

 

Un trial clinico cercherà di dimostrare l’efficacia di Algatrium Plus nei soggetti affetti da Atassia.

 

L’Associazione spagnola Ataxias en Movimiento (Atassie in Movimento) sta collaborando ad un trial clinico atto a ridurre lo stress ossidativo nei pazienti con atassia grazie all’apporto di Algatrium Plus, un’unica molecola specifica di DHA che si è  dimostrata efficace nell’attivazione del sistema cellulare antiossidante.

 

Questo studio, iniziato la settimana scorsa, è mirato a dimostrare una riduzione del danno ossidativo in soggetti affetti da Atassia in modo che essi possano ottenere un trattamento con Algatrium Plus. Ventidue soggetti, principalmente con Atassia di Friedreich (18) e proporzionalmente altri quattro con altre forme di atassia  stanno prendendo parte a questo trial. L’età dei partecipanti varia dai 20 ai 40 anni, ad ecccezione di una ragazza di 17 anni e due pazienti di 62 anni.  Questo studio proseguirà per tre mesi; i partecipanti verranno sottoposti mediamente a tre analisi per valutare la diminuzione dello stress ossidativo. Algatrium Plus consiste in una sostanza sicura in quanto ha superato con successo le prime due fasi fondamentali, inclusa quella della mancanza di tossicità. Se al termine di questo periodo i risultati saranno quelli attesi, il trattamento continuerà in modo indefinito  e sarà disponibile per tutti i pazienti affetti da atassia. Secondo Isabel González dell’Associazione Ataxias en Movimiento: “Il punto principale è che una volta rivelati i risultati, una volta dimostrati i risultati positivi, le conclusioni verranno inoltrate alle autorità sanitarie e alle istituzioni in modo tale che Algatrium Plus possa essere fornito gratuitamente alle persone affette da questa patologia”. Joan Carles Domingo,  chimico dell’Università di Barcellona e coordinatore di questo trial in qualità di ricercatore presso il dipartimento di ricerca di Brudy Technology, ha affermato: ”Entro tre mesi attendiamo una conferma della riduzione del danno ossidativo e a lungo andare un crollo in tutte le patologie correlate che possono colpire le persone affette da atassia, come il diabete o la perdita della visione periferica. Speriamo anche di osservare una riduzione nella gravità delle depressioni, spesso causate da malattie di questo genere”. Le atassie rappresentano una condizione caratterizzata da una perdita progressiva della coordinazione del movimento del corpo. Si tratta di un processo degenerativo altamente debilitante per il quale non esiste ancora un trattamento efficace. L’Associazione Ataxias en Movimiento sostiene una battaglia incessante per eradicare questa malattia e migliorare la qualità di vita delle persone colpite da questa patologia. Per Isabel González: ”Le atassie non hanno mai suscitato l’interesse dell’industria farmaceutica ma dopo aver ricevuto petizioni dai pazienti che stavano già assumendo Algatrium Plus per conto proprio abbiamo contattato i ricercatori della Brudy Technology  che ci hanno dimostrato il loro interesse per le malattie genetiche e, soprattutto, per portare avanti questo progetto”.  

 

°°°°°°°°

 

 

Nota di FA_babelFAmily:

 

sul DHA e Brudy Technology vedi anche

http://health.groups.yahoo.com/group/FA_babelFAmily/message/1803 (ITA)

 


#2063 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Mon Jul 28, 2008 8:37 pm
Subject: FRA: message de Daniela
gippirintronet
Offline Offline
Send Email Send Email
 
 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2044 (ITA)

 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2058 (ESP)

 

Traduction: Henriette Champsaur

 

 

Note de babelFAmily: Daniela est une patiente Italienne AF qui suit une double thérapie: Ferriprox et Lokomat. Pour de plus amples informations, cliquez sur les liens suivants :

 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/1515 (FRA)

http://health.groups.yahoo.com/group/FA_babelFAmily/message/1982 (FRA) 

 

 

 

Message diffusé avec la permission de Daniela.

 

De : Daniela 

A : Gippi 

Envoyé : vendredi 23 juillet 2008 à 21h44

Sujet :  Bonjour

 

 

 

Salut Giampi,

 

Avant tout, je veux te saluer parce que les vacances arrivent et d’ici peu je m’en vais et aussi pour te donner de mes nouvelles, te faire savoir comment je vais en ce moment.

A ce jour, j’ai réussi à conserver ce que j’ai acquis à l’hôpital, puis j’ai obtenu une meilleure position du tronc et du cou et également des améliorations dans les mains et pour quelques exercices comme planter des clous et faire tourner le  rubicube, tout cela s’est amélioré et je le fais plus vite.

 

La masse musculaire a augmenté un peu dans tout le corps.

 

Je commence à obtenir une meilleure position quand je suis debout avec le poids du corps  sur mes deux jambes et ma voix est également plus claire.

 

A bientôt et bonnes vacances.

 

DANY

 

 


#2062 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Mon Jul 28, 2008 7:57 pm
Subject: ENG: FA families rafting trip
gippirintronet
Offline Offline
Send Email Send Email
 
#2060 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Mon Jul 28, 2008 12:31 pm
Subject: ENG: FA related article - Crippling disease secret uncovered
gippirintronet
Offline Offline
Send Email Send Email
 

 

http://www.thewest.com.au/default.aspx?MenuID=2&ContentID=87545

 

Crippling disease secret uncovered

28th July 2008, 15:09 WST

 

Australian scientists have made a key breakthrough in a rare disease that leaves children crippled and wheelchair-bound by their teens.

The Sydney research team has discovered what triggers Friedreich's ataxia, a degenerative disease that attacks the muscles, nervous system and heart of children and leads to an early death due to heart problems.

Well known New York-based Australian artist, Theresa Byrnes, 39, suffers from the disease.

The condition is caused by a build-up of toxic iron in the body's cells, and now a team from the University of Sydney understands why.

"Our study examines the actual reason for why the disease develops and demonstrates for the first time the processes responsible for the iron loading," said Des Richardson, a professor of cancer cell biology at the University of Sydney.

He said understanding toxic iron accumulation opened up the possibility of developing drug treatments that could remove it.

"In fact, using novel drugs that remove the toxic iron, we were able to demonstrate that they could prevent some heart complications in an animal model of Friedreich's ataxia."

The team is carrying out further studies to investigate the effectiveness of the new drugs in preventing the neurodegenerative aspect of the disease.

Friedreich's ataxia is a rare, genetically inherited disease that affects males and females equally, severely impacting their coordination and walking but not their mental capacity.

There is no known cure but the condition can be managed, often into a person's 50s, with orthopaedic appliances, physical therapy and medication for heart problems.

The findings are published in the US journal Proceedings of the National Academy of Sciences.

AAP


#2059 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Mon Jul 28, 2008 11:29 am
Subject: ENG: Science News - Key Mechanism Of Cellular Damage In Aging And Disease Discovered
gippirintronet
Offline Offline
Send Email Send Email
 
 

http://www.sciencedaily.com/releases/2008/07/080724123241.htm

 

Key Mechanism Of Cellular Damage In Aging And Disease Discovered

 

ScienceDaily (July 26, 2008) — Researchers have taken a first snapshot of how a class of highly reactive molecules inflicts cellular damage as part of aging, heart disease, stroke, cancer, diabetes, kidney disease and Alzheimer's disease to name a few. According to a study published July 24 in the journal Cell, researchers have discovered a tool that can monitor related damage and determine the degree to which antioxidant drugs effectively combat disease.

 

Reactive oxygen species (ROS), which include free radicals, are highly reactive molecules that force change upon many molecules they encounter. The body uses ROS to signal for wound healing and to destroy invaders. Excess amounts, however, damage sensitive cell components, including proteins and DNA, in a process called oxidative stress. ROS are kept in check by the body's natural antioxidants, but when uncontrolled can lead to disease.

These highly reactive molecules are created as a side effect when structures within all human cells, the mitochondria, use oxygen to convert food into energy for life. Researchers once thought that altered mitochondrial function was important only in rare genetic diseases, but recent studies have revealed that oxidative stress plays a role in conditions that afflict many millions of patients. As a result, mitochondrial medicine is gaining momentum as groups like the Mitochondria Interest Group at the National Institutes of Health, professional societies and drug companies push basic science toward drug discovery.

"Our study provides a better glimpse of why a cell under assault by disease makes 10 times as many reactive oxygen species as the same cell when healthy," said Shey-Shing Sheu, Ph.D., professor of Pharmacology and Physiology at the University of Rochester Medical Center, and a study author. "We have discovered a chemical tool for investigating how diseases cause damage, mitochondrion by mitochondrion, which should represent a tremendous advance as both a disease biomarker and for drug discovery."

 

Meltdown at the Powerhouse

 

The primary role of mitochondria is to convert food into chemical energy in the form of adenosine triphosphate (ATP), the molecule used by all human cells to store energy. To drive ATP production, electrons are passed along a series of enzymes, but a few "leak" during the process. Leaked electrons react with available oxygen to form the reactive oxygen species, termed superoxide. The emerging theory is that excess superoxide production causes the mitochondria to swell and rupture, resulting in a "cellular energy crisis" that ultimately leads to cell death in the many diseases of oxidative injury.

In the Cell study, researchers used a newly patented, protein-based probe to discover, and make visible, for the first time, fleeting bursts of superoxide production in mitochondria termed "superoxide flashes." The superoxide bursts oxidize cysteine residues in the probe, causing it to emit fluorescent light, which can then be detected and analyzed for patterns. Experiments not only identified superoxide flashes for the first time, but also confirmed that they exhibit a similar size and duration, regardless of the cell type they occur in. This uniform pattern of low-level superoxide production in the mitochondria of healthy cells is normal, perhaps keeping the ROS signaling system ready to fire, researchers said. The one quality of superoxide flashes found to vary was frequency, which dramatically increased during disease.

The research team looked at one kind of oxidative stress in particular: that caused when the oxygen supply to the heart is initially cut off (e.g. during a heart attack or stroke) and then re-established. When heart muscle cells were exposed to a non-oxygen solution for six hours, superoxide flash frequency decreased four-fold, to one event per 100 seconds. Upon re-introduction of oxygen, superoxide production increased eight-fold, confirming past work that re-oxygenation after a heart attack comes with a burst of destructive and uncontrolled superoxide production and oxidative stress.

Existing methods for measuring superoxide production involve chemical indicators or older protein probes, but these previous methods are not specific for superoxide, are damaged by light and provide a limited signal above background noise. The new probe is more sensitive, specific to superoxide, provides a stronger signal than other probes, and is the first to permit reversible measurements of superoxide levels on a millisecond timescale. The research team also created a genetically engineered mouse that expresses the probe within the mitochondria of all of its cells. These "superoxide mice" will enable researchers in the future to quantify the impact of uncontrolled mitochondrial superoxide production across many diseases.

Efforts to develop antioxidant drugs (e.g. vitamin E) to treat diseases of increased oxidative stress have met with limited success to date because they tried to eliminate ROS, rather than maintain the right amount, Sheu said. He established the Mitochondrial Research & Innovation Group (MRIG) at the Medical Center in 2002 with the goal of designing therapies to deliver precise amounts of antioxidants to the mitochondria of diseased cells only. MRIG teams are, for example, screening through compounds to confirm that oxidative stress can be reversed by mitochondria-specific drugs. The new superoxide flash probe will provide a powerful tool for determining the effectiveness of new classes of antioxidant drugs in reducing superoxide production at the right place and time.

The "birthday" for superoxide flashes came in June of 2003 in the lab of Robert Dirksen, Ph.D., associate professor of Pharmacology and Physiology at the Medical Center, when Linda Groom observed spontaneous bursts of fluorescent light using the newly developed protein-based superoxide indicator.

 

The current paper's lead author was Wang Wang, Ph.D. formerly a postdoctoral fellow at the National Institute on Aging at the National Institutes of Health. Aiwu Cheng, Jinhu Yin, Weidong Wang, Edward Lakatta and Mark Mattson also contributed from the NIH, as did Joseph Kao from the University of Maryland. Also contributing from Peking University in Beijing were Huaqiang Fang, Wanrui Zhang, Jie Liu, Xianhua Wang, Kaitao Li, Peidong Han, Ming Zheng, and Heping Cheng, the corresponding author.

"One co-author on the current paper, Dr. Cheng of Peking University, 15 years ago published a seminal study regarding local calcium release events, or calcium sparks," Dirksen said. "This study has been cited more than 900 times and has provided a major contribution to our understanding how the heart beats and why it fails. We believe that our serendipitous discovery of local mitochondrial superoxide flash events could be even more important because superoxide flash frequency may provide an accurate, real-time picture of how uncontrolled oxidative stress contributes to the progression of several, debilitating cardiovascular and neurological diseases."

 


Adapted from materials provided by University of Rochester Medical Center, via EurekAlert!, a service of AAAS.

 

 

 


#2058 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Mon Jul 28, 2008 6:20 am
Subject: ESP: Mensaje de Daniela
gippirintronet
Offline Offline
Send Email Send Email
 
 
 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2044 (ITA)

Traducción: MariLuz González Casas

 

Nota de babelFamily: Daniela es una paciente italiana con ataxia de Friedreich, en terapia con Ferriprox (quelantes de hierro) y Lokomat. Para más información, ir a los siguientes  links:

http://health.groups.yahoo.com/group/FA_babelFAmily/message/1507 (ESP)

http://health.groups.yahoo.com/group/FA_babelFAmily/message/1980 (ESP)

 

 

 

Mensaje difundido con la autorización de Daniela.

 

De: Daniela

Para:  "gippi"

Enviado el: miércoles, 23 de Julio, 2008 9:44 PM

Asunto: saludos

 

 

Hola Giampi,

 

Ante todo quería saludarte porque se acercan las vacaciones y dentro de poco tiempo  me marcharé; además quería mantenerte informado sobre cómo me va.

Hasta hoy he conseguido mantener la mejoría adquirida en el hospital, además tengo mejor postura de tronco y cuello, unido a una mejoría de movimientos y coordinación. En algunos movimientos manuales y en algunos ejercicios como por ejemplo, manejar las figuras ensartables  y rotar el cubo ruso, he conseguido hacerlo de forma más correcta y más rápida.

La masa muscular aumentó un poco en todo el cuerpo.

He mejorado la postura cuando estoy de pie con el peso sobre ambas piernas, y también la voz es más clara.

Hasta pronto y felices vacaciones

Dany

 


#2057 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Sun Jul 27, 2008 10:29 pm
Subject: ESP: Halladas las neuronas responsables de la recuperación en fase de reposo.
gippirintronet
Offline Offline
Send Email Send Email
 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2036 (ITA)

 

Traducción: MariLuz González Casas

 

 

Nota de FA_babelFAmily: importante descubrimiento para combatir el insomnio. Dado que los enfermos de ataxia suelen presentar problemas de insomnio, hemos considerado que  este descubrimiento científico puede ser de interés.

 

 

http://www.ansa.it/opencms/export/site/notizie/rubriche/altrenotizie/visualizza_new.html_730022782.html

 

22-07-2008

 

Cerebro- Halladas las neuronas responsables de la recuperación en fase de  reposo.

Descubiertas las  " neuronas del reposo", células de la corteza cerebral activadas sorprendentemente durante el sueño profundo – es decir, cuando el cerebro se recupera  del cansancio del día - con una probable función restauradora para el cerebro. Esta  observación se debe a un estudio publicado por la  Academia Americana de las Ciencias “PNAS”. “Hasta ahora”, explica a la ANSA  Thomas Kilduff que dirige este estudio en la Facultad de Biociencias  de Menlo Park en California, “se pensaba que las neuronas de la corteza se activaban  solamente durante la fase REM del sueño, es decir, durante los sueños, pero que se desactivaban durante  el sueño profundo restaurador. Las neuronas activadas  durante el sueño, llamadas nNOS, podrían tener un papel importante en la recuperación de funciones mentales que se regeneran durante el sueño profundo", opina Kilduff, el descubrimiento podría pues ser importante para el tratamiento del insomnio y en las perturbaciones del humor y de la  memoria, debidos a la falta de sueño. El sueño profundo es la fase más importante de las horas que pasamos durmiendo porque es la fase durante la cual el cerebro se recupera. Cuanto más cansados estamos, más tiempo dura esta fase en la cual se registran ondas cortas en el cerebro. La amplitud de las ondas cortas depende a su vez del grado de cansancio. Anteriormente se pensaba que durante esta fase crucial del sueño, todas las neuronas de la corteza permanecían desactivadas. Pero los investigadores aislaron de la corteza cerebral de  distintos animales esta  pequeña familia  de neuronas que se comportan de manera diferente, activándose  justamente  durante el sueño profundo. Se trata de neuronas que producen óxido de nitrógeno (NO), un regulador natural del flujo de sangre en el cerebro, cuyo nombre es  nNOS. Los expertos han comprobado incluso que el número de neuronas nNOS activadas en el sueño profundo es proporcional a la  amplitud de las ondas cortas, es decir, al cansancio acumulado. Las  nNOS podrían pues estar relacionadas  con la producción de estas ondas reparadoras - supone Kilduff - o en cualquier caso con  la función de estas mismas ondas.  El hecho mismo de que las nNOS  estén activadas  cuando se desactiva el resto de las neuronas de la corteza - concluye  Kilduff - significa que desarrollan una función importante y nuestro próximo paso será ver qué ocurre  si se interrumpe su actividad.”

 


#2056 From: Mary Kearney <drkearney@...>
Date: Sun Jul 27, 2008 9:06 pm
Subject: Isabelle
drkearney@...
Send Email Send Email
 
Hi

I am sorry to hear of Isabelles death, Please convey my sympathy to
Phillippe


Mary Kearney Ireland

#2055 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Sun Jul 27, 2008 8:12 pm
Subject: ESP: Las células madre de la médula espinal podrían actuar como sistema de reparación nerviosa
gippirintronet
Offline Offline
Send Email Send Email
 
 

 

 

Las células madre de la médula espinal podrían actuar como sistema de reparación nerviosa

Cultivadas en laboratorio y luego reimplantadas en el cuerpo, podrían conducir a tratamientos no quirúrgicos



(FUENTE: Massachusetts Institute of Technology, news release, July 21, 2008)

MARTES, 22 de julio (HealthDay News/Dr. Tango) -- Investigadores de EE. UU. y Suecia han identificado células madre adultas que podrían resultar valiosas en los esfuerzos por desarrollar tratamientos no quirúrgicos para las lesiones de la médula espinal.
Señalaron que podría ser posible desarrollar medicamentos que mejoren la capacidad de estas células madre para reparar las células nerviosas dañadas.
La médula espinal de un adulto contiene sólo un pequeño número de células madre, que proliferan despacio o en contadas veces y no promueven la regeneración por su propia cuenta. Pero algunas investigaciones han mostrado que las células madre de la médula espinal cultivadas en laboratorio y reimplantadas en el lugar de la lesión han restablecido algunas funciones físicas en roedores y primates paralíticos.
En este nuevo estudio, científicos del Instituto Picower de aprendizaje y memoria del MIT en Cambridge, Massachusetts, y del Instituto Karolinska en Estocolmo hallaron que las células madre neurales en la médula espinal adulta están limitadas a una capa de células llamadas células ependimales, que conforman la membrana delgada que recubre los ventrículos en la parte interior del cerebro y la columna central que conecta con la médula espinal.
"Hemos sido capaces de marcar genéticamente esta población de células madre neurales y luego dar seguimiento a su comportamiento. Hallamos que estas células proliferan después de una lesión en la médula espinal, migran hacia el lugar de la lesión y se diferencian varios meses después", dijo en un comunicado de prensa del MIT el autor del estudio Konstantinos Meletis.
"La capacidad de las células ependimales para diferenciarse en varios tipos de células después de una lesión hace que sean muy interesantes desde el punto de vista de la intervención. Imagínese que pudiéramos regular el comportamiento de esta población de células madre para reparar células nerviosas dañadas", destacó Meletis.
La investigación fue publicada en la edición de julio de PLoS Medicine.

 

Más información

El U.S. National Institute of Neurological Disorders and Stroke tiene más información sobre la lesión de médula espinal.

Artículo por HealthDay, traducido por Dr. Tango

Derecho de Autor © 2008 ScoutNews, LLC. Todos los derechos reservados.


#2054 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Sat Jul 26, 2008 9:48 pm
Subject: FRA: adieu à Isabelle
gippirintronet
Offline Offline
Send Email Send Email
 
 
 
Emis par Sylvie le: Sam 26 Juil 2008 à 20:13     Sujet du message: adieu à isabelle
        
bonjour tous

je reviens auprès de vous avec une bien triste nouvelle qui me bouleverse énormément... philippe hennebert vient de m'appeler pour m'annoncer qu'isabelle sa jeune épouse AF est décédée jeudi soir...

malgré la maladie isabelle rayonnait de joie de vivre... et elle avait trouvé l'amour de sa vie auprès de philippe pour qui elle était tout... ils étaient si beaux tous les deux...

isabelle de là où tu es j'espere que tu vois tous ceux qui t'aiment et que tu es en paix...
philippe je fais l'impossible pour venir auprès de toi lundi dire adieu à isabelle, tu peux compter sur moi et sur mon amitié... tient bon mon ami... je suis déjà avec toi...

philippe et isabelle en avril dernier :


#2053 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Sat Jul 26, 2008 6:52 am
Subject: ENG: Cuba Will Show in World Congress Advances in Genomic Medicine
gippirintronet
Offline Offline
Send Email Send Email
 

http://www.cubaheadlines.com:80/2008/07/19/12483/cuba_will_show_world_congress_advances_genomic_medicine.html

 

 

Cuba Will Show in World Congress Advances in Genomic Medicine

 

Sat, 2008-07-19 04:48

 

Cuba’s achievements in the field of genomic medicine will be showed during the 3rd International Congress on Hereditary Ataxia that will take place in the eastern province of Holguin from October 1-3 later this year.

 

Specialists from Spain, Germany, Portugal, the United States, Mexico, Guatemala, and other Latin American countries, will participate in the meeting to discuss aspects related to therapies for the treatment of this disease.

Speaking to
ACN, Dr. Luis Velásquez, Director of the Center for the Research and Rehabilitation
from Hereditary Ataxias in Holguin, said that this disease affects 10 to 15% of the world population.

Among the countries with the highest rates are Mexico, India, Italy, Germany, Spain and the United States.

Velasquez said that the
etiology
of ataxias is still unknown but he said that there is a genetic damage or mutation in a group of this kind of disease. This transformation, he noted, produces an abnormal protein that causes the death of a group of structures of the nervous system.

(Adelante.cu)

 

°°°°°°°

 

FA_babelFAmily note:

see also

http://health.groups.yahoo.com/group/FA_babelFAmily/message/1990 (ENG)

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2001 (ESP)

 

 

 


#2052 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Fri Jul 25, 2008 6:22 pm
Subject: ENG: FA related article - Church group opts for home front mission
gippirintronet
Offline Offline
Send Email Send Email
 
 

http://www.courierpress.com/news/2008/jul/25/church-group-opts-for-home-front-mission/?gleaner=1/

 

 

Church group opts for home front mission

 

Susie Davis was at a loss for words as she tried to express the gratitude that she felt for members of Community Baptist Church on Thursday.

"It's like a big huge embrace from a loving family that I've never had before," Davis said after she found the words she was searching for.

The Henderson resident is one of about five families in Henderson who saw their homes worked on by other members of their community this week.

Tim Hobbs, the pastor at Community Baptist Church, said that they usually plan a mission trip, but this year they wanted to help people in their own community.

"There are people here who need our help," he said.

This is the first year that the church has done this kind of mission work in the community, but Hobbs said he hopes that this is the start of something new.

Hobbs said this work is a part of fulfilling God's mission.

"It's up to us to give back," he said.

The church mission team began work on Monday and they've worked from about noon to 7 p.m. every day, church member Jica Crafton said.

Crafton said she liked seeing the progress that she and other church members have made on the houses they've worked on.

"Everything we've done has left a mark," she said.

Davis' house on Washington Street isn't the only house in Henderson that has seen renovations and upgrades. About 20 church members have worked on about five other sites painting, helping with yard work and staining decks.

"We don't deserve it," Davis said. "There are other people who need it."

Davis lives in her house with her son, Kevin Gentry.

"To sit and watch your property deteriorate is so painful," Davis said. "Especially when you've been the type who has done anything and everything."

Gentry was diagnosed with Friedreich's Ataxia, a genetic disorder that affects the nervous system, when he was 16 and Davis has been taking care of him since.

Davis said Gentry has defied the odds, and is a "miracle"-- doctors told her not to expect him to live past 21.

"If it wasn't for his church family he would have given up," she said.

Davis said that Community Baptist has been a huge help to her and her son.

Gentry, who is in a wheelchair, sat on his deck as it was being stained to visit with the church members.

"I think it's great that they take the time, not only for us, but for other people in the city," Gentry said.

Davis said she is so thankful for the work that she could sit and stare at her freshly painted garage all day.

"We're blessed to have a roof over our head and doubly blessed to have them do this work," Davis said.

 


#2051 From: "Gian Piero Sommaruga" <gsommaruga@...>
Date: Fri Jul 25, 2008 4:28 pm
Subject: ENG: Cells For Spinal-Cord Repair Could Lead To Non-Surgical Treatment For Injuries
gsommaruga@...
Send Email Send Email
 

 

http://health.groups.yahoo.com/group/FA_babelFAmily/message/2050 (ITA)

 

 

 

http://www.medicalnewstoday.com/articles/115773.php

 

MIT Identifies Cells For Spinal-Cord Repair - Could Lead To Non-Surgical Treatment For Injuries

 

Article Date: 23 Jul 2008 - 0:00 PDT

 

A researcher at MIT's Picower Institute for Learning and Memory has pinpointed stem cells within the spinal cord that, if persuaded to differentiate into more healing cells and fewer scarring cells following an injury, may lead to a new, non-surgical treatment for debilitating spinal-cord injuries.

The work, reported in the July issue of the journal PLoS (Public Library of Science) Biology, is by Konstantinos Meletis, a postdoctoral fellow at the Picower Institute, and colleagues at the Karolinska Institute in Sweden. Their results could lead to drugs that might restore some degree of mobility to the 30,000 people worldwide afflicted each year with spinal-cord injuries.

In a developing embryo, stem cells differentiate into all the specialized tissues of the body. In adults, stem cells act as a repair system, replenishing specialized cells, but also maintaining the normal turnover of regenerative organs such as blood, skin or intestinal tissues.

The tiny number of stem cells in the adult spinal cord proliferate slowly or rarely, and fail to promote regeneration on their own. But recent experiments show that these same cells, grown in the lab and returned to the injury site, can restore some function in paralyzed rodents and primates.

The researchers at MIT and the Karolinska Institute found that neural stem cells in the adult spinal cord are limited to a layer of cube- or column-shaped, cilia-covered cells called ependymal cells. These cells make up the thin membrane lining the inner-brain ventricles and the connecting central column of the spinal cord.

"We have been able to genetically mark this neural stem cell population and then follow their behavior," Meletis said. "We find that these cells proliferate upon spinal cord injury, migrate toward the injury site and differentiate over several months."

The study uncovers the molecular mechanism underlying the tantalizing results of the rodent and primate and goes one step further: By identifying for the first time where this subpopulation of cells is found, they pave a path toward manipulating them with drugs to boost their inborn ability to repair damaged nerve cells.

"The ependymal cells' ability to turn into several different cell types upon injury makes them very interesting from an intervention aspect: Imagine if we could regulate the behavior of this stem cell population to repair damaged nerve cells," Meletis said.

Upon injury, ependymal cells proliferate and migrate to the injured area, producing a mass of scar-forming cells, plus fewer cells called oligodendrocytes. The oligodendrocytes restore the myelin, or coating, on nerve cells' long, slender, electrical impulse-carrying projections called axons. Myelin is like the layer of plastic insulation on an electrical wire; without it, nerve cells don't function properly.

"The limited functional recovery typically associated with central nervous system injuries is in part due to the failure of severed axons to regrow and reconnect with their target cells in the peripheral nervous system that extends to our arms, hands, legs and feet," Meletis said. "The function of axons that remain intact after injury in humans is often compromised without insulating sheaths of myelin."

If scientists could genetically manipulate ependymal cells to produce more myelin and less scar tissue after a spinal cord injury, they could potentially avoid or reverse many of the debilitating effects of this type of injury, the researchers said.

This study was supported by grants from the Swedish Research Council, the Swedish Cancer Society, the Foundation for Strategic Research, the Karolinska Institute, EuroStemCell and the Christopher and Dana Reeve Foundation.

Source: Deborah Halber
http://www.mit.edu

 


#2050 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Fri Jul 25, 2008 12:25 pm
Subject: ITA: cellule staminali per riparare lesioni al midollo spinale
gippirintronet
Offline Offline
Send Email Send Email
 
 

http://www.aduc.it/dyn/salute/noti.php?id=227760

 

AMERICHE - USA
Studio: cellule staminali per riparare lesioni al midollo spinale

 

24 Luglio 2008

 

Ricercatori del MIT Picower Institute for Learning and Memory di Cambridge, Massachusetts, e del Karolinska Institute di Stoccolma rivelano che potrebbe essere possibile migliorare le lesioni alla spina dorsale usando le cellule staminali, e senza ricorrere ai bisturi. Gli scienziati hanno dichiarato, infatti, che potrebbe essere prodotto, nel futuro, un medicinale in grado di migliorare le possibilita' che hanno le cellule staminali di riparare i danni al sistema nervoso.
Il midollo spinale di un adulto contiene solo un piccolo numero di cellule staminali, che si riproducono lentamente, sono molto rare e non si riproducono facilmente, ma la ricerca ha dimostrato che le cellule staminali del midollo possono riprodursi in laboratorio e inserendole nella lesione e' possibile ripristinare le funzioni paralizzate. L'esperimento e' stato testato su cavie e primati.
Gli scienziati hanno scoperto che le cellule staminali neurali del midollo sono posizionate su cellule denominate ependimali. "Siamo stati in grado di marcare geneticamente queste cellule staminali neurali e di seguirne il comportamento. Abbiamo cosi' scoperto che si riproducono sulle lesioni al midollo spinale, migrano attraverso tutta la lesione e si "differenziano" nei mesi seguenti. L'abilita' delle cellule ependimali di trasformarsi in diverse cellule le rende interessanti. Immaginiamo, se si potesse controllarne il comportamento, di riparare cosi' i danni alle cellule nervose", ha dichiarato Konstantinos Meletis del MIT.

 

 


#2049 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Fri Jul 25, 2008 12:21 pm
Subject: ENG: Experts At Anavex Offer A Primer On Promising 'Oxidative Stress' Theory
gippirintronet
Offline Offline
Send Email Send Email
 
 
 
 
 
Article Date: 25 Jul 2008 - 1:00 PDT
 

Experts At Anavex Offer A Primer On Promising 'Oxidative Stress' Theory


As trials on anti-amyloid vaccines continue to fail in the search for a viable Alzheimer's drug, a new approach - oxidative stress - is starting to emerge as a contender.

Anavex Life Sciences (AVXL.OB) is leading this promising avenue of research. It has developed an Alzheimer's drug candidate based on the theory that oxidative stress, not amyloid-beta plaques, is the cause of the disease. Oxidative stress is a type of damage to the body's tissues caused by the destructive action of certain forms of oxygen.

To help people better understand the science behind oxidative stress, Anavex offers this helpful primer:

What is Oxidative stress?

We are all familiar with processes like the rusting of iron, oil and butter turning rancid and fruits turning brown after prolonged exposure to air. All these phenomena are caused by exposure to oxygen in a process known as oxidation. Similar effects are known to happen inside our bodies in the molecular and cellular level, all because of the destructive action of a form of oxygen known as Reactive Oxygen Species (ROS). This destructive nature of oxygen comes in contrast to its unconditional necessity for the survival of all living aerobic organisms.

The term oxidative stress is used to describe a state in which the equilibrium between the production of ROS and the body's protective mechanisms (antioxidants and repair mechanisms) has been compromised, resulting in the oxidative damage of cells, tissues and organs. Moreover, ROS in the state of oxidative stress can impair several cellular signaling pathways that may result in the onset of age related diseases.

The Oxidative Stress And Alzheimer's Disease

A growing number of publications have supported the idea that oxidative stress may be the real cause of Alzheimer's. For example, in "Involvement of Oxidative Stress in Alzheimer's Disease," published in the Journal of Neuropathology and Experimental Neurology in 2006, study leader Dr. Akihiko Nunomura pointed to extensive evidence of mechanistic and chronological links between oxidative stress and a number of key characteristics of the disease.

Interestingly, this research also suggests that amyloid beta, which can act as an anti-oxidant, could in fact be initially produced by the body as it tries to combat the disease, only later turning toxic as the substance accumulates in large amounts. In other words, amyloid-beta could be the body's early protective reaction to the disease - suggesting that its removal from the brain during the early stages of Alzheimer's could in fact do more harm than good.

This theory is consistent with a number of factors for which the amyloid-beta hypothesis has been unable to account. There are reports, for instance, of individuals with amyloid-beta loads equivalent to Alzheimer's patients who do not suffer from the disease, as noted by R. J. Castellani et al in a 2006 article in the American Journal of Alzheimer's Disease and Other Dementias.

In addition, scientists have found a weak correlation between the amount of amyloid beta present in the brains of Alzheimer's sufferers and the severity of the illness. Furthermore, even though some test drugs reduce the amount of amyloid-beta in the brain, this is not correlated with substantial improvements in cognitive functioning.

Promising Pre-clinical Studies

Meanwhile, Anavex's alternative approach is showing great promise in early-stage testing. Anavex's drug candidate, known as ANAVEX 1-41, uses sigma receptors, a unique class of receptor molecules, to guard against oxidative stress and repair cells compromised by its effects. In advanced pre-clinical studies, ANAVEX 1-41 appeared to provide neurons with potent protection from oxidative stress. It also prevented amyloid beta from becoming toxic and causing any follow-on damage. Moreover, ANAVEX 1-41 reduced memory deficits in animal test subjects - a particularly notable finding, given the quest for a drug that can actively reverse the effects of the disease.

A program of further work is currently underway to further assess the compound, including ongoing pre-clinical studies being carried out in collaboration with the Université Montpellier in France. The company is moving forward aggressively with this work, which is designed to pave the way for a rapid move towards human testing, expected to commence in late 2008 or early 2009.

While much still needs to be done, Anavex is enormously pleased with its progress to date on this promising new approach to combating one of the world's most complex and devastating diseases.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases such as Alzheimer's and depression. The company's proprietary SIGMACEPTOR™ Discovery Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.
http://www.anavex.com

ANAVEX's SIGMACEPTOR™-N program involves the development of novel and original drug candidates that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, etc.) The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for anti-amnesic, neuroprotective, anti-apoptotic, anti-oxidative, anti-inflammatory, anti-convulsive, anti-depressant and anxiolytic properties. The company believes that oxidative stress, not amyloid-beta, is the cause of Alzheimer's. ANAVEX 1-41, uses sigma receptors, a unique class of receptor molecules, to guard against oxidative stress and repair cells compromised by its effects. So far, through the advanced pre-clinical phase of development, the compound has performed extremely well in well-recognized animal models of Alzheimer's disease, underscoring the promise of this alternative approach to the disease.

ANAVEX SIGMACEPTOR™-C program involves the development of novel and original drug candidates targeting cancer. The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid cancers such as colon, prostate, breast and lung. ANAVEX 7-1037 has already demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.


#2048 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Thu Jul 24, 2008 6:33 pm
Subject: DEU: Santhera erwartet negative Empfehlung für SNT-MC17/idebenone in Friedreich-Ataxie
gippirintronet
Offline Offline
Send Email Send Email
 


Santhera Pharmaceuticals Holding AG    

Published: 19:03 24.07.2008 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649

Laufende Studien verunmöglichen CHMP-Prüfung unter Richtlinie für kleine Patientenpopulationen - Santhera erwartet negative Empfehlung für SNT-MC17/idebenone in Friedreich-Ataxie

Santhera Pharmaceuticals (SWX:SANN), ein auf neuromuskuläre Erkrankungen fokussiertes Schweizer Spezialitätenpharmaunternehmen, gibt heute bekannt, dass das Committee for Medicinal Products for Human Use (CHMP) der europäischen Arzneimittelbehörde (EMEA) Santhera informell darüber orientiert hat, dass die Zulassung von SNT-MC17/idebenone zur Behandlung der Friedreich-Ataxie zum heutigen Zeitpunkt keine positive Empfehlung erhalten wird. Gemäss diesen Informationen kann das Committee die Richtlinie für klinische Studien in kleinen Patientenpopulationen (Guideline on Clinical Trials in Small Populations) wegen den gut vorangehenden Phase-III-Studien nicht für den Antrag auf Marktzulassung anwenden. Santhera geht davon aus, dass das Medikament erst dann eine positive Empfehlung seitens des Committes erhalten kann, wenn die Resultate zumindest einer dieser beiden Studien vorliegen.
 
Resultate der klinischen Studien mit SNT-MC17/idebenone, welche die CHMP im Rahmen des Zulassungsverfahrens erhalten hat, zeigen statistisch und klinisch relevante Verbesserungen bei Friedreich-Ataxie-Patienten in alltäglichen Aktivitäten (Activities of Daily Living) sowie in kardiologischen und neurologischen Funktionen. In seinem Joint-Assessment-Bericht bestätigt das Committee, dass sowohl das Sicherheitsprofil, die präklinischen Daten als auch die technische Entwicklung von SNT-MC17/idebenone den Anforderungen für eine Zulassung entsprechen. Dennoch kommt die CHMP zum Schluss, dass die eingereichten Daten zum Wirkungs-/Risiko-Profil unter den üblichen klinischen Prüfrichtlinien nicht für eine Zulassung ausreichen. Der Antrag auf Marktzulassung basierte primär auf den positiven Daten der NICOSIA-Studie (NIH COllaboration with Santhera in Ataxia), einer gemeinsam mit den US National Institutes of Health durchgeführten klinischen Studie mit jugendlichen Friedreich-Ataxie-Patienten. Das Dossier umfasste neurologische und kardiologische Auswertungen dieser Daten sowie Resultate früherer, klinischer Studien seitens akademischer Forschungsinstitute, welche primär die positive Wirkung auf Erkrankungen des Herzmuskels (Kardiomyopathie) in einer breiteren Population aufgezeigt hatten.
 
"Die zum jetzigen Zeitpunkt mündlich kommunizierte negative Empfehlung der CHMP kommt überraschend und ist eine herbe Enttäuschung. Basierend auf früheren Gesprächen im Rahmen des Zulassungsprozesses hatten wir erwartet, dass unser Dossier unter der Richtlinie für klinische Versuche in kleinen Patientenpopulationen geprüft wird", erklärt Klaus Schollmeier, Chief Executive Officer von Santhera. "Als wir den Antrag auf Marktzulassung stellten, lief die Patientenrekrutierung unserer europäischen Phase-III-Studie MICONOS nur schleppend, weshalb wir über die Wahrscheinlichkeit eines erfolgreichen Abschlusses innerhalb eines vernünftigen Zeitrahmens eher besorgt waren. Zu diesem Zeitpunkt war darüber hinaus unsere Phase-III-Studie IONIA in den USA noch nicht gestartet. Wir haben die CHMP laufend über den Status der beiden Studien informiert. Jetzt scheint es, dass sich unser Erfolg, dennoch in der Lage zu sein, weitere Daten zu erheben, gegen uns wendet. Zusammen mit unserem Partner Takeda werden wir nun mögliche Optionen prüfen, damit SNT-MC17/idebenone in Europa so bald als möglich als kontrolliertes pharmazeutisches Produkt zur Behandlung der Friedreichs-Ataxie eingesetzt werden kann."
 
Die EMEA verfügt über einen formalen Prozess, unter welchem ein Unternehmen Einsprache zu einer negativen CHMP-Empfehlung erheben und eine weitere Prüfung durch ein gesondertes wissenschaftliches Gremium (Scientific Advisory Group) verlangen kann. In einem solchen Fall könnte eine abschliessende Empfehlung innerhalb von sechs Monaten vorliegen. Santhera und Marketingpartner Takeda werden diese Möglichkeit sorgfältig prüfen. Sollte diese Option verfolgt werden, gilt eine 15-tägige Einsprachefrist nach offiziellem Erhalt der CHMP-Empfehlung.
 
Status der laufenden Phase-III-Studien
In Europa sind rund 90 % der für die Phase-III-Studie namens MICONOS (Mitochondrial Protection With Idebenone In Cardiological Or Neurological Outcome Study) notwendigen Patienten rekrutiert. Bis Ende Jahr sollte die Rekrutierung abgeschlossen sein.
 
In den USA sind bereits 41 Patienten in die Phase-III-Studie namens IONIA (Idebenone effects On Neurological ICARS Assessments) eingeschlossen. Santhera hat sich letztes Jahr mit der US Food and Drug Administration unter einem Special Protocol Assessment darauf geeinigt, mindestens 51 Patienten zu rekrutieren und, falls möglich, noch weitere Patienten einzuschliessen. Aufgrund der aktuellen Aussicht auf weitere Studienteilnehmer erwarten Santhera und die US-Studienleiter, dass die Studie schlussendlich zwischen 60 und 65 Patienten umfassen wird.
 
Überblick über die Pipeline und finanzieller Ausblick
Santhera wird anlässlich der für 22. August 2008 geplanten Publikation des Halbjahresberichts 2008 über den Status der gesamten klinischen Pipeline und die finanziellen Kennzahlen informieren.
 
Conference call
At 19.00 CET / 18.00 UKT / 13.00 EST on July 24, 2008, Santhera will host a conference call (in English only). Anyone interested in participating may join the teleconference facility using the following dial-in in Switzerland +41 52 267 07 36. The conference call will be recorded for playback and is available one hour after the conference call ends and for 20 days under +41 52 267 07 00 (reference no. 668713).
 
The Company was informed by the CHMP at 18:36 CET and acknowledges the late-breaking nature of this news. Management will be available after the call as well as all day Friday to respond to questions from anyone who missed the opportunity to participate in the live teleconference conference.  
 
 

Über Friedreich-Ataxie
Friedreich-Ataxie ist eine seltene, aber schwere, genetisch bedingte neuromuskuläre Erkrankung, die zur Degeneration von Nerven- und Muskelgewebe führt. Diese Krankheit führt zum Verlust von Muskelkontrolle, zu unkoordinierten Bewegungen, zu Muskelschwund und zur Verdickung der Herzwände. Aus diesem Grund beträgt die durchschnittliche Lebenserwartung von Friedreich-Ataxie-Patienten lediglich ungefähr 35 bis 50 Jahre. Friedreich-Ataxie betrifft die männliche und weibliche kaukasische Bevölkerung gleichermassen. In Nordamerika und Europa sind schätzungsweise 20'000 Patienten von der Krankheit betroffen.
 
Friedreich-Ataxie wird durch einen genetischen Defekt in dem für Frataxin kodierenden Gen verursacht. Geringere Mengen dieses Proteins führen letztlich zu einer Beeinträchtigung der Energieproduktion in den Mitochondrien, den Energieproduzenten der Zellen sowie zu einer Erhöhung von oxidativem Stress. Primär durch den Frataxin-Mangel betroffen sind die Gewebe mit dem höchsten Energiebedarf, insbesondere Nerven- und Herzgewebe, was zu pathologischen Veränderungen in der Herzmuskelanatomie und -funktion sowie zum Verlust von Nervenzellen führt.
* * *
 
Über Santhera
Santhera Pharmaceuticals (SWX:SANN) ist ein auf neuromuskuläre Erkrankungen fokussiertes Schweizer Spezialitätenpharmaunternehmen, das sich auf die Erforschung, die Entwicklung und die Vermarktung von niedermolekularen Medikamenten spezialisiert hat. Santhera prüft zurzeit drei Wirkstoffe in fünf klinischen Entwicklungsprogrammen. Das erste Produkt, SNT-MC17 (INN: idebenone), hat in Kanada die bedingte Marktzulassung zur Behandlung von Friedreich-Ataxie erhalten und wird in unter dem Produktnamen Catena® vermarktet. Das Medikament wird zurzeit auch von den Gesundheitsbehörden in der EU und der Schweiz geprüft und befindet sich in den USA in der Zulassungsstudie. Der Wirkstoff hat auch positive Wirkung in Duchenne-Muskeldystrophie, einer zweiten Indikation gezeigt. Weitere Informationen zu Santhera finden Sie unter www.santhera.com.
 
 
Für weitere Auskünfte wenden Sie sich bitte an:
Klaus Schollmeier, Chief Executive Officer
Telefon +41 (0)61 906 89 52
klaus.schollmeier@...
 
Barbara Heller, Chief Financial Officer
Telefon +41 (0)61 906 89 54
barbara.heller@...
 
Thomas Staffelbach, Head Public & Investor Relations
Telefon +41 (0)61 906 89 47
thomas.staffelbach@...
 
 

Disclaimer / Zukunftsgerichtete Aussagen
Diese Publikation stellt kein Angebot oder Einladung dar, um Wertschriften von Santhera Pharmaceuticals Holding AG zu erwerben oder zu zeichnen. Diese Veröffentlichung kann gewisse in die Zukunft gerichtete Aussagen über Santhera und ihre Geschäftsaktivitäten enthalten. Solche Aussagen beinhalten gewisse Risiken, Unsicherheiten und andere Faktoren, die zur Folge haben können, dass tatsächlich erzielte Geschäftsresultate, finanzielle Verfassung, Leistungsfähigkeit und Zielerreichung wesentlich von dem abweichen, was in solchen Aussagen implizit oder explizit erwähnt ist. Leserinnen und Leser sollten diesen Aussagen daher kein übermässiges Gewicht beimessen; dies ganz besonders nicht im Zusammenhang mit Verträgen oder Investitionsentscheiden. Santhera übernimmt keine Verpflichtung, diese in die Zukunft gerichteten Aussagen zu aktualisieren.
 
Diese Mitteilung ist eine Übersetzung der verbindlichen englischen Originalversion.


News release CHMP

#2047 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Thu Jul 24, 2008 6:08 pm
Subject: ENG: Santhera Expects Negative CHMP Opinion on MAA for SNT-MC17/Idebenone in Friedreich's Ataxia
gippirintronet
Offline Offline
Send Email Send Email
 

 
Santhera Pharmaceuticals Holding AG    

Published: 18:58 24.07.2008 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649

Santhera's Ongoing Studies Prevent CHMP Review under Small Patient Populations Guideline - Company Expects Negative CHMP Opinion on MAA for SNT-MC17/Idebenone in Friedreich's Ataxia

Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has informally advised Santhera that it would not support a positive opinion for the Marketing Authorization Application (MAA) for SNT-MC17/idebenone to treat patients with Friedreich's Ataxia at this time. According to the information received, Santhera's ongoing phase III trials prevented the CHMP from reviewing the Company's application under the EMEA Guideline on Clinical Trials in Small Populations as requested by Santhera in its MAA filing. The Company's understanding is that the Committee believes it cannot approve the drug before data from at least one of Santhera's advanced phase III clinical programs in Europe and the United States are submitted for review.
 
In clinical studies submitted to the CHMP as part of the approval process, SNT-MC17/idebenone showed statistically and clinically relevant improvements in Friedreich's Ataxia patients, as measured by Activities of Daily Living scores as well as in cardiac and neurological functions. The CHMP Joint Assessment Report supports the safety profile, preclinical data and technical development of SNT-MC17/idebenone as sufficient to potentially meet its criteria for approval. However, the CHMP concluded that Santhera had not submitted a sufficient set of data demonstrating a clear positive risk/benefit balance for approval under the Committee's standard clinical review guidelines. The MAA filing was based primarily on positive pediatric data generated in the NICOSIA (NIH COllaboration with Santhera in Ataxia) study, a collaborative trial with the US National Institutes of Health, analyzing a variety of neurological and cardiac outcome measures and was supported by evidence from several academic trials in a wider population that demonstrated efficacy in the treatment of cardiac hypertrophy in Friedreich's Ataxia patients.
 
Klaus Schollmeier, Chief Executive Officer of Santhera, commented: "The possible negative CHMP opinion is obviously disappointing and surprising as well. Based on earlier discussions, we had expected to qualify for the EMEA Guideline on Clinical Trials in Small Populations. When we submitted the MAA, our European phase III clinical trial MICONOS was running, but we were very concerned about our enrollment prospects. At that time, our US phase III trial IONIA had not even yet started. We kept the Committee informed about the status of both trials throughout the MAA filing process. It seems that our success in gathering additional data has been working against us. Together with our partner Takeda, we will evaluate our options for making SNT-MC17/idebenone available as a controlled pharmaceutical product to Friedreich's Ataxia patients in Europe as soon as feasible".
 
The EMEA has a formal process whereby the MAA sponsor may request reexamination of the CHMP's initial negative opinion, including a review of the dossier by an independent specialist Scientific Advisory Group. If Santhera requests such a review, a final opinion could be rendered within approximately six months. Santhera together with its marketing partner Takeda are evaluating this option carefully. If this alternative is pursued, the appeal must be submitted within the next 15 days from the official CHMP opinion.
 
Update on ongoing Phase III clinical trials
In Europe, the MICONOS (Mitochondrial Protection With Idebenone In Cardiological Or Neurological Outcome Study) phase III trial has currently enrolled approximately 90% of the patients needed to complete recruitment and is on track for full enrollment by the end of 2008.
 
 
Pipeline Status and Updated Financial Guidance
Santhera will provide information on the status of its entire development pipeline and to update on financial guidance as part of its Half-Year Financial Results Report on August, 22, 2008.
 
Conference call
At 19.00 CET / 18.00 UKT / 13.00 EST on July 24, 2008, Santhera will host a conference call. People interested in participating may join the teleconference facility using the following dial-in in Switzerland +41 52 267 07 36. The conference call will be recorded for playback and is available one hour after the conference call ends and for 20 days under +41 52 267 07 00 (reference no. 668713).
 
The Company was informed by the CHMP at 18:36 CET and acknowledges the late-breaking nature of this news. Management will be available after the call as well as all day Friday to respond to questions from anyone who missed the opportunity to participate in the live teleconference conference.  
 
About Friedreich's Ataxia
Friedreich's Ataxia is a rare but severe genetic neuromuscular disorder that results in the degeneration of an individual's nerve and muscle tissue. This disorder causes loss of muscle control, uncoordinated movements, muscle wasting and thickening of heart walls which frequently leads to a shortened life span. Friedreich's Ataxia affects both Caucasian males and females equally and it is estimated that about 20,000 patients suffer from the disease in both North America and Europe. Average life expectancy for Friedreich's Ataxia patients is limited to approximately 35 to 50 years.
 
The disorder results from a genetic defect in the gene encoding for frataxin. Reduced levels of this protein ultimately result in impaired energy production in mitochondria, the cells' energy production centers, and elevated oxidative stress. Tissues that have the highest need for energy, in particular nerve and cardiac tissues, are primarily affected by frataxin deficiency resulting in pathological changes in heart muscle anatomy and function and loss of nerve cells.
 
* * *
 
About Santhera
Santhera Pharmaceuticals (SWX: SANN) is a Swiss specialty pharmaceutical company focused on the discovery, development and marketing of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases, an area of high unmet medical need which includes many orphan indications with no current therapy. Santhera currently investigates three compounds in five clinical-stage development programs. The Company's first product, SNT-MC17 (INN: idebenone), has received a marketing approval with conditions from Health Canada to treat Friedreich's Ataxia and will be marketed under its brand name Catena®. The product is also under review by health authorities in the EU and in Switzerland, while in the United States, a pivotal phase III trial is recruiting patients. SNT-MC17/idebenone has also shown efficacy in a phase II clinical trial as a potential treatment for the indication Duchenne Muscular Dystrophy. For further information, please visit www.santhera.com.
 
For Further Information, Contact
Klaus Schollmeier, Chief Executive Officer
Phone: +41 (0)61 906 89 52
klaus.schollmeier@...
 
Barbara Heller, Chief Financial Officer
Phone: +41 (0)61 906 89 54
barbara.heller@...
 
Thomas Staffelbach, Head Public & Investor Relations
Phone: +41 (0)61 906 89 47
thomas.staffelbach@...
 
Disclaimer/Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements.
 
 


News release CHMP



 



#2046 From: "Gian Piero Sommaruga" <gsommaruga@...>
Date: Thu Jul 24, 2008 12:52 pm
Subject: ENG: FA related article - The American University of Beirut adopts accommodating attitude toward students with disabilities
gsommaruga@...
Send Email Send Email
 

http://www.dailystar.com.lb/article.asp?edition_id=1&categ_id=1&article_id=94419

 

AUB adopts accommodating attitude toward students with disabilities

Daily Star staff
Thursday, July 24, 2008

 

 

BEIRUT: For Fawzi Yassin, who graduated this year with a degree in computer science, academic standards were not his only motivation for choosing to study at the American University of Beirut (AUB) - an accommodating attitude was a high priority.

Fawzi is one of at least a dozen disabled students who graduated from AUB over the past decade. But he was the only one this year who rolled on his wheelchair to receive his degree from then-President John Waterbury during the June commencement exercises.

Stricken with a debilitating genetic disease - Friedreich's ataxia - that damages the nervous system and leaves its victims with impaired mobility as well as other symptoms, Fawzi needed a university that could provide him with easy access to classes. While AUB's 150-year-old, hilly campus is not ideal to a wheel-chair-bound individual, the university's administration was eager to accommodate its prospective student.

So when Fawzi applied in 2005, the Faculty of Arts and Sciences promised to reschedule any classes that proved inaccessible to him. A year later, the Protection Office bought a wheel-chair accessible car to transport disabled students along with their wheel chairs across campus, and particularly from upper to lower campus and vice versa.

While AUB does not receive many disabled students every year, it has a policy to equip all new buildings with ramps and disabled-friendly bathrooms. As for the old buildings, they are gradually being provided with disabled access. "We are very keen to make our disabled student population feel comfortable and at home," said Dean of Student Affairs Maroun Kisirwani.

Disabled students who wish to study at AUB may also benefit from the Women's League Scholarship Fund for Handicapped Students, which was established in 1999. Several disabled students were awarded financial assistance from this scholarship fund. During the academic year 2005-06, the recipient was Fawzi Yassin.

The Red Cross Youth club at AUB also offers services to students with special needs, helping them around campus and with their studies through the 25-year-old Room for Visually-Challenged Students, which is jointly run with the Office of Student Affairs. The room offers a variety of services, such as turning books into audio tracks, through a computer software or student volunteers, and an archive of taped university text books. "Our volunteers also read for visually-impaired students and help them with their online and library searches," said Rayya Fallis, the president of the Red Cross AUB Youth Club.

Fawzi's experience at AUB changed his perspective on life. Before joining the university, he saw his world as confined to his parents' home, with no prospects for a future. Now, he plans to enroll in a master's program at AUB and work part-time.

"Before joining AUB, I did not think of going to work, and thought I would live at home forever. Now I have lots of hope for the future," he said. "AUB built my personality and allowed me to make lots of friends. I am so thankful for that opportunity and would like to tell people: Never to lose hope. Always keep your eye on the goal and don't think it's impossible." - The Daily Star

 

 


#2045 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Thu Jul 24, 2008 12:15 pm
Subject: ENG: Kyoto U. centers to provide ES-derived cells
gippirintronet
Offline Offline
Send Email Send Email
 

http://www.yomiuri.co.jp/dy/features/science/20080723TDY02201.htm

 

 

July 23, 2008

 

 

Kyoto U. centers to provide ES-derived cells

The Yomiuri Shimbun

Kyoto University and some research centers will launch a project this year to provide institutions with nerve cells grown from human embryo-stem (ES) cells, The Yomiuri Shimbun has learned.

The project is expected to help accelerate new drug development and research into the causes of neurological disorders, including Alzheimer's, Lou Gehrig's disease and Huntington's disease.

As part of the project, researchers will implant specific types of genes, known to cause neurological diseases, into human ES cells. Researchers will make the ES cells, which can be transformed into various types of cells, grow into neurons, which they will then provide to research centers for study.

As part of its research into Alzheimer's, a team including Kyoto University Prof. Norio Nakatsuji has succeeded in introducing a causative gene into human ES cells.

 


#2044 From: "Gian Piero Sommaruga \(casa\)" <gippi@...>
Date: Thu Jul 24, 2008 6:44 am
Subject: ITA: messaggio di Daniela
gippirintronet
Offline Offline
Send Email Send Email
 

 

Messaggio diffuso con l’autorizzazione di Daniela.

 

 

From: Daniela

To:  "gippi"

Sent: Wednesday, July 23, 2008 9:44 PM

Subject: Saluti

 

 

Ciao Giampi,

 

innanzi tutto volevo salutarti perchè si avvicinano le vacanze e fra poco parto e poi per raccontarti le news di come sto andando.
Ad oggi sono riuscita a mantenere quello che avevo acquisito in ospedale, poi ho ottenuto una posizione migliore con il tronco e con il collo e anche nei movimenti e  nella coordinazione. Inoltre in alcuni movimenti manuali e in alcuni esercizi come infilare i chiodini e roteare il cubo russo sono diventata più corretta e più veloce.

La massa muscolare è aumentata un po' in tutto il  corpo.

Ho incominciato a ottenere una posizione più corretta quando sto in piedi portando il carico su entrambe le gambe e anche la voce è piu' chiara.
A risentirci a presto e buone vacanze.
Dany

 


Messages 2044 - 2074 of 3331   Newest  |  < Newer  |  Older >  |  Oldest
Advanced
Add to My Yahoo!      XML What's This?

Copyright © 2009 Yahoo! Inc. All rights reserved.
Privacy Policy - Terms of Service - Guidelines - Help